PROVIDING THE ADVANCED ORTHOPEDIC SOLUTIONS OF TOMORROW, TODAY
RevOrtho is focused on advancing orthopedic technology in order to better protect and preserve biology. Our technology is designed to improve in preservation of bone tissue, venous and arterial systems, and soft tissue, in order to improve performance of equipment and implants, as compared to prior technology. We also focus on providing individualized solutions to complex orthopedic challenges through innovation, allowing a wide range of implantation options. We have intellectual property for novel solutions over a wide scope of orthopedic sub-specialities and other applications.
Craig E. Klinger
Craig E. Klinger is co-founder and CEO of RevOrtho. Responsibilities include intellectual property and product development, and
organizational planning. Craig Klinger has over 20 years of experience in medical research, and specifically in the field of orthopaedic research and has managed multiple orthopedic research projects including labratory-based and clinical investigations. Responsibilities have included research oversight from conception to final analysis and reporting, which has lead to numerous publications and presentations at national and international conferences. This experience has been greatly beneficial to RevOrtho as scientific research is fundamental in development of our core technology.
Jose B. Toro, MD
Dr. Jose B. Toro is co-founder of RevOrtho. Responsibilities include intellectual property and product development and
organizational planning. Dr. Toro is fellowship trained, at the Hospital for Special Surgery, and a board-certified orthopaedic surgeon in practice for 10 years, and specializes in orthopaedic trauma and metabolic bone disease. His major areas of interest include hip preservation, orthopaedic trauma, treatment of injuries of the hip, pelvis, and acetabulum, as well as degenerative bone disease, aging, osteoporosis and metabolic bone conditions. Dr. Toro currently serves as Director of Orthopaedic Trauma, Bone Metabolism and Hip Preservation Surgery at the KMI Division of Piconic Bay Medical Center, in Suffolk County, New York. Dr. Toro’s research has been published in peer-reviewed orthopaedic journals, including the Journal of Trauma, Injury Journal, the Journal of Bone and Joint Surgery, Archives of Orthopaedic and Trauma Surgery, and other leading orthopaedic journals. He has presented research at annual meetings of the Orthopaedic Trauma Association, the American Association of Orthopaedic Surgeons, the Orthopaedic Research Society, and at conferences in the United States, Canada, Puerto Rico and South America. He has served as a member of the Graduate Medical Education Committee of Weill Cornell Medical College, and as Assistant Professor of Orthopaedic Surgery at New York’s Albert Einstein College of Medicine. Dr. Toro initially began his clinical career at the James J. Peters Veterans Affairs Medical Center in Bronx, New York, and followed by Jacobi Medical Center in Bronx, New York.
David L. Helfet, MD
Dr. Helfet’s responsibilities with RevOrtho include intellectual property and product development. Dr. Helfet also serves as Chief of Orthopedic Trauma Service for the Hospital for Special Surgery and NY Presbyterian Hospital, professor of Orthopedic Surgery at Weill Cornell Medicine, and is annually ranked as one of Castle-Connolly's publication, “America's Top Doctors.” Dr. Helfet is a world-renowned orthopedic surgeon, and has served as a member of the Board of Directors of Synthes, Chairman of AO Clinical Investigation and Documentation, President of the Orthopaedic Trauma Association, and member of the American Academy of Orthopaedic Surgeons and examiner of the American Board of Orthopaedic Surgery. Dr. Helfet is a globally published surgeon and the recipient of many honors and awards including the Presidential Guest and Watson-Jones Memorial Lecture of the British Orthopaedic Association. He was most recently inducted in the Johns Hopkins Society of Scholars and is currently designated as the Orthopedic Trauma specialist for the Fire Department of New York (FDNY), the New York Police Department (NYPD), and the New York State Police. Dr. Helfet received a BSc in Biochemistry and an M.B.CH.B from the University of Cape Town, completed his internship at Edendale Hospital in Pietermaritzburg, South Africa; his surgical and orthopedic residencies at Johns Hopkins University; his Trauma fellowship at the University of Bern/Insel Hospital, in Bern, Switzerland; and his Sports Medicine Fellowship at UCLA.
THE FUTURE OF HIP PRESERVATION IS HERE
January 10, 2017
Our revolutionary patented system for Modular Hip Resurfacing (MHR) has biological and biomechanical advantages over prior Hip Resurfacing Arthroplasty (HRA) systems. Numerous MHR implantation options allow scalable fixation for individualized patient applications.
Existing HRA systems put the nutrient arteries to the femoral head and femoral neck at high risk. Protection of the hip nutrient arteries is vital for success in HRA and for minimizing risk of postoperative aseptic loosening and avascular necrosis (AVN). Our MHR system instruments and implants protect both the nutrient arteries and bone of the femoral head and femoral neck. Our system allows uncemented application to eliminate cement thermal necrosis. Additionally, there are multiple biomechanical advantages to the MHR system. These include the ability to provide lateral fixation and protect against femoral neck fracture, and also to allow increased construct support which may especially benefit women and provide a HRA option. Furthermore, MHR provides the capability to individually address variable bone quality and AVN Ficat stages, eliminates femoral neck notching risk and retains a femoral head collar for construct support, and facilitates increased compression to along the implant-bone interface and porous undersurface. These advantages help to maximize biologic preservation intraoperatively and postoperatively to enhance operative outcomes over prior systems.
Contact RevOrtho to learn more about this revolutionary system.
NEW PATELLOFEMORAL RESURFACING ARTHROPLASTY
August 20, 2017
A new patellofemoral resurfacing arthroplasty system is coming soon. Our patellofemoral resurfacing system is designed to better protect the native biology of the knee joint and allow uncemented implantation options. It is also designed to encourage osseous-integration with between the system components and underlying bone tissue. More details will be coming soon.
MORE NEWS SOON
March 25, 2017
RevOrtho continues to develop innovative solutions for a wide range of orthopedic conditions affecting the upper and lower extremities. Please stay tuned over the coming weeks for additional news about patent pending technology we are concurrently working on. We are excited about the newest innovations we are working on which will improve outcomes for those in need of improved orthopedic solutions.